Our partner is a clinical-stage biopharmaceutical company that develops small molecule therapeutics with novel mechanisms of action for the treatment of severe life-threatening diseases with no approved or effective therapy. Most of their programs are targeting indications in Neurology, Nephrology, and Rare Disease.

This critical hire worked closely with global business partners to drive alignment across the portfolio in preparation for going public. They led key initiatives and assigned projects and programs, such as annual operating plans, executive presentations, dashboard and analytics, and operating efficiencies for the commercial portfolio.